Russia’s Federal Biomedical Agency said it has developed a drug for the treatment of COVID-19.
The agency said its drug was based on mefloquine, which is used to prevent or treat malaria.
Preliminary tests show the drug will provide effective treatment for COVID-19 patients with varying severity.
According to the agency’s statement, the drug prevents virus replication in cells and as a result, stops the inflammatory process caused by the virus.
Veronika Skvortsova, the agency’s head, said Mefloquine has to be combined with antibiotics for the maximum effect, allowing an increase in the concentration of antiviral agents in blood plasma and lungs.
“This will ensure effective treatment of patients with various degrees of coronavirus infection,” Skvortsova said.
The agency said it was developing an effective and safe scheme for the prevention of coronavirus on the basis of mefloquine.
The Agency said it developed the treatment after a careful understudy of the Chinese and French experience with similar drugs.
Unlike other countries, Russia is experiencing an explosion in pneumonia related cases.